Streamlining Aetna Prior Authorization for Dermatology Practices

Mastering Aetna prior authorization for dermatology is critical for timely patient access to essential treatments, from biologics to Mohs surgery.

Dermatology practices frequently encounter complex prior authorization requirements for high-cost medications and specialized procedures. Navigating Aetna's specific submission channels, medical necessity criteria, and re-authorization workflows can strain revenue cycle operations and delay patient care.

Aetna's Prior Authorization Channels for Dermatology Services

For medical benefit requests, including many dermatology procedures and specialty injectables, Aetna (CVS Aetna) primarily routes through the Availity provider portal. X12 278 electronic transactions are also supported for applicable procedure categories. Outpatient pharmacy-benefit prior authorizations, common for many dermatology biologics, are administered via CVS Caremark, accepting submissions through CoverMyMeds or Surescripts ePA.

Key Dermatology Services Requiring Aetna Prior Authorization

Biologics for psoriasis (e.g., Dupixent, Cosentyx, Tremfya, Skyrizi)
Biologics for atopic dermatitis (e.g., Dupixent, tralokinumab)
Biologics for hidradenitis suppurativa (e.g., adalimumab)
Mohs micrographic surgery, particularly for non-melanoma skin cancers in sensitive areas
Advanced skin cancer treatments, including immunotherapy
Select specialty topicals and phototherapy regimens

Navigating Aetna's Medical Necessity Criteria for Dermatology

Aetna publishes its medical necessity criteria for dermatology services within its Clinical Policy Bulletins (CPBs), which are publicly available and versioned. These CPBs often align with established clinical guidelines, such as those from the American Academy of Dermatology (AAD) for conditions like psoriasis and atopic dermatitis, or NCCN guidelines for skin cancers. Documentation typically requires evidence of disease severity (e.g., PASI, EASI, BSA scores), trials of prior conventional therapies (topicals, phototherapy, systemic agents), and specific screenings (e.g., TB, hepatitis) before biologic initiation.

Common Aetna Prior Authorization Denial Reasons in Dermatology

Failure to document required step therapy, such as prior trials of conventional systemic agents for psoriasis biologics.
Insufficient documentation of disease severity using standardized scoring systems (PASI, EASI, BSA).
Lack of documented pre-biologic screenings (e.g., TB, hepatitis).
Mismatch with AAD Appropriate Use Criteria (AUC) for Mohs surgery regarding site or tumor type.
Non-adherence to biosimilar substitution protocols where applicable.

Klivira's Solution for Aetna Dermatology Prior Authorization

Klivira streamlines the Aetna prior authorization process for dermatology practices by integrating with existing EMRs to automate data submission and intelligent criteria matching. Our platform incorporates AAD-guideline-aware logic for biologics, validates Mohs surgery against AUC, and manages periodic re-authorization workflows for chronic treatments. This reduces administrative burden and accelerates patient access to care by ensuring submissions meet Aetna's specific requirements.

Understanding Aetna's Electronic PA and Turnaround Times

Aetna (CVS Health Aetna) supports X12 278 transactions for medical benefit PA, and partners with CoverMyMeds and Surescripts for outpatient pharmacy ePA. Turnaround times for Aetna prior authorizations are influenced by state-mandated minimums and NCQA Utilization Management accreditation standards. For Medicare Advantage, Medicaid, CHIP, and QHP lines, CMS-0057-F mandates 72-hour standard and 24-hour expedited decisions, with compliance phased through 2027. The commercial line of business is not directly impacted by CMS-0057-F.

Frequently asked questions

How does Aetna differentiate between medical and pharmacy benefit for dermatology biologics?

The benefit assignment for dermatology biologics often depends on the specific drug, its administration route (e.g., self-injected at home vs. infused in a clinic), and the Aetna plan's formulary. While many outpatient, self-administered biologics fall under the pharmacy benefit (managed by CVS Caremark), certain infused or specialty injectables may be managed under the medical benefit, requiring different submission channels.

What are common documentation requirements for Aetna prior authorization of psoriasis biologics?

Aetna typically requires documentation of a confirmed diagnosis, disease severity using metrics like PASI or BSA, and evidence of prior treatment failures. This often includes trials of topical therapies, phototherapy, and conventional systemic agents (e.g., methotrexate). Additionally, pre-biologic screenings for conditions like tuberculosis and hepatitis are usually mandatory.

Where can I find Aetna's medical necessity criteria for Mohs surgery?

Aetna's medical necessity criteria for Mohs micrographic surgery are published in its Clinical Policy Bulletins (CPBs). These CPBs outline the specific indications, tumor types, and anatomical sites that qualify for coverage, often referencing Appropriate Use Criteria (AUC) established by professional organizations like the AAD. Always consult the most current CPB version for applicable policies.

Does Aetna accept electronic prior authorization for dermatology services?

Yes, Aetna supports electronic prior authorization for various dermatology services. For medical benefit requests, X12 278 transactions are accepted, and the Availity portal serves as a primary submission channel. For pharmacy benefit medications, Aetna's PBM, CVS Caremark, partners with ePA platforms like CoverMyMeds and Surescripts for retail pharmacy submissions.

What are the typical appeal pathways for a denied Aetna prior authorization for dermatology?

If an Aetna prior authorization for dermatology is denied, practices typically have several appeal levels. These often include reconsideration, a peer-to-peer review with an Aetna medical director, and a formal internal appeal. For commercial lines, external review by an independent review organization may be available after exhausting internal appeals, following state-specific regulations.